Abstracts tagged "ankylosing spondylitis (AS) and psoriatic arthritis"

Abstract Number: 552 • 2019 ACR/ARP Annual Meeting
In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients
Herbert Kellner¹, ¹Praxis Prof. Herbert Kellner, Munich, Germany
Background/Purpose: Background: Biosimilar TNFα inhibitors have only become available in the last few years. Etanercept bisosimilar SB-4 Benepali® has been launched in March 2016 in…
Abstract Number: 2399 • 2019 ACR/ARP Annual Meeting
Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis
Carlos Sánchez-Piedra¹, María Colazo ², Rosa Roselló ³, Cristina Campos ⁴, P. Vela ⁵, Cristina Bohorquez ⁶, Carolina Pérez-García ⁷, Manuel Pombo-Suarez ⁸, Carlos Fernández-López ⁹, Dolores Ruiz-Montesinos ¹⁰, Fernando Alonso ¹¹, Federico Diaz-Gonzalez ¹² and Juan Jesús Gómez-Reino ¹³, ¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²Hospital de Burgos, Burgos, ³Hospital San Jorge, Huesca, ⁴Hospital General de Valencia, Valencia, ⁵Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ⁶Universitary Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcala de Henares, Spain, ⁷Rheumatology, Hospital del Mar, Barcelona, Catalonia, Spain, ⁸Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ¹⁰Hospital Virgen Macarena, Sevilla, ¹¹Unidad Investigación SER, Madrid, Spain, ¹²Hospital de Canarias, Tenerife, ¹³Hospital de Santiago, Santiago de Compostela
Background/Purpose: During the past 15 years, advancements in the understanding of the safety and effectiveness, as well as the expanding access and availability of biologic…
Abstract Number: 2621 • 2018 ACR/ARHP Annual Meeting
Predictors of Survival of Adalimumab Treatment in the Management of Ankylosing Spondylitis and Psoriatic Arthritis in Canadian Routine Care
Louis Bessette^1,2, Majed Khraishi³, Jacqueline Stewart^4,5, Andrew Chow^6,7, Viktoria Pavlova⁸, Brandusa Florica^6,9 and Valencia P. Remple^10,11, ¹Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ²Rheumatology, Laval University, Quebec, QC, Canada, ³Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Penticton Regional Hospital, Penticton, BC, Canada, ⁵University of British Columbia, Penticton, BC, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Trillium Health Partners Credit Valley Hospital, Mississauga, ON, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Trillium Health Partners, Mississauga, ON, Canada, ¹⁰AbbVie Corporation, Montreal, QC, Canada, ¹¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Biologics therapy survival is often used as a proxy for treatment effectiveness and safety. However, it may be influenced by patient characteristics, utilization patterns,…
Abstract Number: 140 • 2015 ACR/ARHP Annual Meeting
Identifying Psoriatic Arthritis and Ankylosing Spondylitis Patients Responsible for the Highest Costs of Care: Data from a Large US Cohort
Jacqueline B. Palmer, Yunfeng Li, Vivian Herrera and Minlei Liao, Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: The economic burden of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in the biologics era is not well understood in the US population. Using…
Abstract Number: 1601 • 2014 ACR/ARHP Annual Meeting
Are There Gender Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Ankylosing Spondylitis and Psoriatic Arthritis?
John Kelsall¹, William Bensen², Wojciech Olszynski³, Niall Jones⁴, Isabelle Fortin⁵, Andrew Chow⁶, Milton Baker⁷, Saeed Shaikh⁸, Denis Choquette⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, May Shawi¹¹, Francois Nantel¹¹, Susan Otawa¹² and Allen J Lehman¹², ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Dept of Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁵Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁶McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ⁷University of Victoria, Victoria, BC, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose The prevalence of ankylosing spondylitis (AS) is 2-3 times higher in men compared to women whereas psoriatic arthritis (PsA) is generally considered a disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].